Lymphoma nini ya B-cell lymphoma (DLBCL)-04

Igisubizo cya Bwana Monger gitangaje: Ubuvuzi bwa Dual CD19/CD20 CAR-T buzana ibyiringiro bishya kuri DLBCL yongeye kugaruka

Amavuriro y'umurwayi 

Rodney Charles Monger, umugabo w'imyaka 68 ukomoka mu mahanga, yasanzwemo indwara ya lymphoma ya B-cell lymphoma (DLBCL) imyaka itatu mbere yaho. Yashakiye ubuvuzi bw’inyongera mu bitaro bya Tianjin Cancer muri Kanama 2025. Isuzuma rya lymph node yo mu mura ryemeza ko lymphoma ya B-cell lymphoma ikomoka ku mibare y’uturemangingo. Immunohistochemistry yagaragaje neza ko CD20, CD19, na CD10, hamwe n’ubwinshi bwa Bcl-6, Bcl-2 (70%+), na c-MYC (60%+). Isuzuma rya gene ryagaragaje ko BCL2 yasubiwemo na FISH na mutations muri gene za EZH2, KMT2D, TNFRSF14, NRAS, na TPMT—ibimenyetso bihuye n’imiterere ikomeye kandi ishobora gutera ibyago byinshi.

Urugendo rw'ubuvuzi bwa mbere 

Muri Kanama 2025, Bwana Monger yahawe pola hamwe n'umuti ugabanya ubukana bwa BTK na lenalidomide. Hanyuma yafashwe na chimiotherapie ya FC (fludarabine + cyclophosphamide). Nubwo yashyizeho izi ngamba, indwara ye yakomeje kugorama, bituma itsinda ry'abaganga risaba Bioocus dual-targeting CD19/CD20 CAR-T therapy.

Ku ya 8 Nzeri 2025, Bwana Monger yahawe selile za CD19/CD20 CAR-T zikozwe mu buryo bwa autologous. Igitangaje ni uko yabyiboneye. indwara yo kutagira irekurwa rya cytokine (CRS)na indwara y’uburozi bw’uturemangingo idatera ingaruka mbi ku bushobozi bw’umubiri bwo kurwanya indwara (ICANS)—inzira yoroshye nyuma yo guterwamo imiti yatumye akomeza kuba umuntu uhamye kandi ufite icyizere kuva ku munsi wa mbere.

Kwaguka kwa Selingi za CAR-T: Kwihuta kandi GukomeyeGukurikirana amaraso yo ku nkengero z'umuyoboro byagaragaje ko uturemangingo twa CAR-T twagutse cyane, byemeza ko twashyizwe mu maraso kandi ko twongera kwiyongera neza:

• D4 nyuma yo kuyitera(Ku ya 12 Nzeri): Uturemangingo twa CAR19+ twari 0.50% by'uturemangingo twa CD3+ T (agaciro kabyo ni 6.04 × 10⁷/L); Uturemangingo twa CAR20+ twari 0.41% (4.96 × 10⁷/L).
• D7(Ku ya 15 Nzeri): CAR19+ yazamutse igera kuri 1.68% (1.40 × 10⁷/L); CAR20+ igera kuri 1.63% (1.36 × 10⁷/L).
• D10(18 Nzeri): CAR19+ yageze ku rwego rwo hejuru 43%y'uturemangingo twa CD3+ T (agaciro kayo ntarengwa 3.13 × 10⁸/L); CAR20+ yageze kuri 32.74%(agaciro ka buri wese 3.26 × 10⁸/L).

Uburyo bwo kugenzura ubwiyongere bw'amaraso mu miyoboro y'amaraso bwagaragaje ko hari uburyo bwo gukwirakwiza CD4+ na CD8+ mu buryo buringaniye, hamwe n'uburyo bwo kugaragaza CAR ebyiri. Imirongo ikurikirana imikorere y'umubiri yagaragaje uburyo bwo kwaguka bw'amajwi mu buryo busobanutse neza, bigaragaza ko igishushanyo cya CD19/CD20 ebyiri cyateje imbere CAR-T ikomeza no kwiyongera mu mubiri.

Uko ibintu bimeze ubu n'uburyo bwo kwita ku babyeyi 

Mu isuzuma riheruka (D10), Bwana Monger akomeje kumererwa neza mu buvuzi. Ari ku miti ikoreshwa mu kunyobwa ikubiyemo acyclovir, sulfamethoxazole, orelabrutinib, lenalidomide, n'imiti ifasha, akurikiranwa buri gihe mu maraso, imikorere y'umwijima n'impyiko, ndetse n'ibimenyetso by'ububyimbirwe nk'uko gahunda yo kuva mu mubiri ibivuga.

Itsinda rya Bioocus ryatanze ubufasha bwuzuye kandi bushingiye ku barwayi muri rusange: icumbi ryiza, amafunguro afite intungamubiri, ubufasha mu gutwara abantu n'ibintu, n'ubujyanama mu by'imitekerereze ya Bwana Monger n'umuryango we. Ubu buryo buhuriweho bwamufashije kwibanda ku gukira byuzuye.

Ubutumwa bw'ibyiringiro 

Urubanza rwa Bwana Monger rugaragaza ubushobozi bwo guhindura imikorere y’ubuvuzi bwa Bioocus dual CD19/CD20 CAR-T ku barwayi bafite DLBCL yongeye kurwara/ifite ikibazo cyo kubura amaraso. Kwaguka vuba kandi gukomeye kw’uturemangingo twa CAR-T tudafite uburozi bukabije bigaragaza umutekano mwiza w’uyu muti n’imikorere ikomeye yo kurwanya ikibyimba—ndetse no ku murwayi ukuze ufite imiterere y’uturemangingo ishobora gutera ibyago byinshi.

Twishimiye gushyigikira abarwayi nka Bwana Monger mu rugendo rwabo rwo gusubira ku buzima. Inkuru nk'ize zishimangira umuhate wacu wo gutanga uburyo bushya bwo kuvura uturemangingo hakoreshejwe ubuvuzi bwihariye.

Iki kibazo gitangwaho raporo ku bwumvikane bw'umurwayi. Ibisubizo bishobora gutandukana; Ibisubizo bya CAR-T biterwa n'imiterere y'indwara ku giti cye n'impamvu z'ubuvuzi. Kugira ngo umenye byinshi cyangwa ushakishe uburyo bwo kuvura, sura urupapuro rwacu rwa CAR-T Therapy for Non-Hodgkin Lymphoma.